Shilpa Medicare Q2 FY27 Results Due as Revenue Forecast Rises

Shilpa Medicare Limited will announce its Q2 FY27 results on November 5, 2026, after analysts increased their 2027 revenue forecast to ₹1,900 crore from ₹1,800 crore. The scheduled disclosure covers the quarter and half year ended September 30, 2026, and follows strong reported growth in the preceding quarter.

When will Shilpa Medicare announce Q2 FY27 results?

Shilpa Medicare will disclose its unaudited standalone and consolidated Q2 FY27 and half-year results on November 5, 2026. The company's Board of Directors is scheduled to meet on that date to consider and approve the financial statements for the quarter and six months ended September 30, 2026.

The company has also scheduled an investor conference call for November 5 at 16:00 IST. The call is expected to provide management commentary after the results disclosure and allow analysts and investors to assess quarterly performance, operating trends and business updates.

The forthcoming announcement is identified as Q2 FY26-27 in the company-related disclosures. Some market-data references describe the same event as Q2 2027, reflecting a financial-year naming convention rather than a separate reporting period.

What did Shilpa Medicare report in the previous quarter?

Shilpa Medicare reported Q1 FY26-27 revenue of ₹465.78 crore, up 6.59% quarter on quarter from ₹436.99 crore and 44.90% year on year. Reported gross profit was ₹101 crore, while net profit was ₹94 crore, according to the provided quarterly financial summary.

The same summary showed gross profit rising 13.42% sequentially and 61.15% from a year earlier. Net profit increased 6.09% quarter on quarter and 99.37% year on year. These figures provide the most recent reported financial reference point before the September-quarter announcement.

Separate historical data in the source lists revenue of ₹466 crore for the June 2026 quarter, broadly consistent with the reported ₹465.78 crore figure after rounding. Quarterly revenue in that data series had risen from ₹370 crore in September 2025 to ₹410 crore in December 2025, ₹437 crore in March 2026 and ₹466 crore in June 2026.

Why have estimates for Shilpa Medicare changed?

Analyst consensus cited in the source has raised Shilpa Medicare's 2027 revenue forecast by ₹100 crore to ₹1,900 crore. The earnings-per-share estimate was also increased to ₹14.77 from ₹13.40 per share, indicating a higher consensus expectation for the company's projected financial performance.

However, the same forecast data expects net income to grow 5.8% next year. That compares with forecast net-income growth of 23% for the Indian pharmaceuticals industry. The figures show that the upward revisions to revenue and EPS estimates coexist with a more modest projected profit-growth rate relative to the sector forecast.

The provided earlier second-quarter data recorded revenue of ₹372 crore, up 8.1% year on year, net income of ₹44.07 crore, up 146%, and earnings per share of ₹2.25, compared with ₹0.92 in the corresponding earlier period. These figures are historical data and should not be treated as the yet-to-be-released Q2 FY27 result.

Which businesses are relevant to Shilpa Medicare's results?

Shilpa Medicare operates across pharmaceutical ingredients, finished dosage formulations, biosimilars and contract development and manufacturing organisation services. Its operations span India, the United States, Europe and other international markets, making the quarterly results relevant across multiple pharmaceutical business lines.

The company-related research material also notes that Nor Ursodeoxycholic acid, described as a first-in-class therapy for fatty liver disease, has been launched in India under the Noduca brand. The material states that the product is being prepared for studies in the United States and Europe, although no financial contribution from the product was provided.

For investors, the November 5 filing and conference call are the scheduled sources for updated revenue, profitability and management commentary. The announcement will also cover the first half of FY27, offering a broader view than the individual September quarter.

Conclusion

Shilpa Medicare enters its Q2 FY27 results date with reported Q1 revenue of ₹465.78 crore and net profit of ₹94 crore, alongside higher consensus forecasts for 2027 revenue and EPS. The key factual context is the contrast between strong recent reported growth and the 5.8% next-year net-income growth forecast, which is below the 23% industry forecast cited in the source.

Investors will next watch the November 5 Board approval, the unaudited September-quarter and half-year figures, and management's 16:00 IST conference call. The disclosed schedule provides the next confirmed opportunity to assess whether reported performance aligns with the revised ₹1,900 crore 2027 revenue estimate.